January 15th 2024
Sumanta Kumar Pal, MD, FASCO, discusses the rationale for treating patients with zanzalintinib in relapsed/refractory clear cell renal cell carcinoma.
March 22nd 2022
Dr. Pal analyzes and reviews the results from long term follow-up data on PFS from the TIVO-3 trial.